UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 8, 2004
STERIS Corporation
(Exact name of registrant as specified in its charter)
| Ohio | 0-20165 | 34-1482024 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 5960 Heisley Road, Mentor, Ohio | 44060-1834 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (440) 354-2600
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| ITEM 7.01. | Regulation FD Disclosure |
Attached hereto as Exhibit 99 is a copy of materials dated September 8, 2004 and prepared with respect to a presentation at the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference that was made by senior management of STERIS Corporation (the “Company”) on September 8, 2004.
The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STERIS CORPORATION | ||
| By: | /s/ Mark D. McGinley | |
| Mark D. McGinley Vice President, General Counsel and Secretary | ||
Dated: September 8, 2004
Exhibit 99
Thomas Weisel Partners
Healthcare Tailwinds 2004
September 8, 2004
Forward-Looking Statements
Except for historical information discussed, today’s presentation includes forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual events or results may differ materially. Some of the factors which could cause actual results to materially differ from those anticipated by the forward-looking statements are set forth in the Company’s latest SEC Filings on Forms 10-K and 10-Q and in its earnings release dated July 27, 2004. Further, these forward-looking statements speak only as of this date September 8, 2004. We undertake no obligation to publicly release the results of any revisions to the forward-looking statements made today to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
2
Sales by Business Segment
Fiscal Year Ended March 31, 2004 (Dollars in millions)
HEALTHCARE ($753)
69%
LIFE SCIENCES ($246)
23%
STERIS ISOMEDIX SERVICES ($88)
8%
3
Healthcare Segment Overview
Products:
Equipment and chemistries for cleaning and sterilizing surgical instruments Surgical tables, lights and ceiling management systems Caregiver skin protection products Maintenance services
Customers:
Hospitals
Outpatient surgical centers Physician offices
Growth Drivers:
Aging population
Inpatient and outpatient surgical procedures Hospital capacity expansions New products and technical innovations Global awareness of the need for infection control
Competitive Position:
Sterile Processing—$3.6 billion market
STERIS US leader Getinge global leader Others: J&J, 3M
Surgical Tables and Lights—$1.5 billion market
STERIS US leader Getinge global leader
Others: Getinge, Skytron, Hill-Rom
Skin Care—$300 million caregiver market
STERIS key player in fragmented market
Competitive Strengths
Integrated offering Broad technology base Strong US channel
4
Life Sciences Segment Overview
Products:
Variety of equipment for aseptic manufacturing and research Sterile water equipment, sterilizers, washers, room decontamination, freeze dryers Cleaning chemistries and service Technologies, products and services for government agency, military and private industry use
Customers:
Pharmaceutical and biopharmaceutical manufacturers Research institutions Government agencies, private industry
Growth Drivers:
Aging population
Increased drug consumption
Industry investment in drug production capacity Rigorous regulatory environments and risk of biochemical incidents Emerging diseases Biological and chemical weapon threats Government spending on homeland defense
Competitive Position:
STERIS has a strong position in $750 million global process equipment market STERIS has a strong position in $500 million research equipment market Others: Getinge, other European manufacturers in a variety of products
Competitive Strengths:
Breadth of product offering Unique offering Global presence Technology leadership
5
STERIS Isomedix Services Overview
Products:
Batch contract sterilization in 16 regional facilities with gamma, ethylene oxide and electron beam processing technologies
Customers:
Medical device manufacturers Food packagers Pharmaceutical manufacturers Cosmetics producers
Growth Drivers:
Outsourcing by manufacturers Growth in medical device consumption Expansion of STERIS processing facilities
Competitive Position:
STERIS US leader in $690 million global market
Competitors:
Sterigenics IBA Surebeam Cosmed Titan Scan
Strengths:
Responsive
Broad capability/technology Strategically located facilities
6
Our Growth Strategy
Enhance our revenue stream by continuing to diversify by product, service, market and geography
Increase recurring revenues Leverage our channel Introduce new technologies Adapt our technologies Expand internationally
7